Across TCGA pan-cancer cohorts, BAZ1A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated BAZ1A data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher BAZ1A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BAZ1A expression acts as an unfavorable survival marker.

ACC, SARC, and STAD are the cancer types where BAZ1A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
SARC	OS	Median	All	0.143	0.745	<.001	6	view →
STAD	DFS	Median	All	0.198	0.587	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: BAZ1A tumor-vs-normal RNA expression · all BAZ1A data types